---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-003725"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:53:09.712804+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cyclerion reports Q3 net loss $11.3M, cash $63M; pipeline advances in CIAS, ADv, MELAS

## Summary
- Net loss of $11.3M improved from $18.8M in Q3 2020; R&D expenses down to $7.0M.
- Cash, cash equivalents, and restricted cash $63M, down from $70M at June 30, 2021.
- First patients enrolled in CIAS study (CY6463); patient screening underway in ADv study.
- MELAS study enrollment slowed by COVID-19; topline clinical results expected H1 2022.
- G&A expenses decreased to $4.6M from $8.0M, driven by lower salaries and financing fees.

## SEC filing metadata
- accession: 0000950170-21-003725
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017021003725/0000950170-21-003725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017021003725/cycn-20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-003725
- JSON: https://secwatch.observer/filing/0000950170-21-003725.json
- Plain text: https://secwatch.observer/filing/0000950170-21-003725.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.